Abstract
Small cell lung cancer (SCLC) invades locally and metastasizes distantly extremely early when compared with nonsmall cell lung cancer (NSCLC). The underlying molecular mechanisms, however, have not been elucidated. Accumulating evidence suggests that downregulation of several members of tetraspanins is associated with progression of solid tumors, thus indicating poor prognosis. Here we screened 30 lung cancer cell lines for expression of tetraspanins, CD9, CD63, CD81, CD82, CD151, and NAG-2. Flow cytometry revealed that, among these proteins, CD9 is broadly expressed in NSCLC lines, but is absent or highly reduced in most SCLC lines (P<0.0001). Using the Boyden chamber and videomicroscopic cell motility assays, we showed that stable transfection of CD9 into an SCLC line, OS3-R5, reduced cell motility on fibronectin. Furthermore, by transient transfection of green fluorescent protein (GFP)-tagged CD9 into three other SCLC lines, we observed that SCLC cells expressing GFP-CD9 were uniformly less motile than untransfected cells. CD9 or GFP-CD9 was associated with β1 integrins and distributed at the tumor cell periphery and cell–cell contacts, suggesting that CD9 modifies β1 integrin function to reduce motility. These findings suggest that low expression of CD9 may contribute to the highly invasive and metastatic phenotype of SCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adachi M, Taki T, Konishi T, Huang CI, Higashiyama M and Miyake M . (1998). J. Clin. Oncol., 16, 1397–1406.
Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M and Miyake M . (1996). Cancer Res., 56, 1751–1755.
Atkinson B, Ernst CS, Ghrist BF, Ross AH, Clark WH, Herlyn M, Herlyn D, Maul G, Steplewski Z and Koprowski H . (1985). Hybridoma, 4, 243–255.
Berditchevski F and Odintsova E . (1999). J. Cell. Biol., 146, 477–492.
Berditchevski F, Tolias KF, Wong K, Carpenter CL and Hemler ME . (1997). J. Biol. Chem., 272, 2595–2598.
Bredin CG, Sundqvist KG, Hauzenberger D and Klominek J . (1998). Eur. Respir. J., 11, 400–407.
Boucheix C, Nguyen-van-Cong Perrot JY, Foubert C, Gross MS, Weil D, Laisney V, Rosenfeld C and Frezal J . (1985). Ann. Genet., 28, 19–24.
Cajot JF, Sordat I, Silvestre T and Sordat B . (1997). Cancer Res., 57, 2593–2597.
Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, Zweig MH and Minna JD . (1985). Cancer Res., 45, 2913–2923.
Claas C, Seiter S, Claas A, Savelyeva L, Schwab M and Zoller M . (1998). J. Cell Biol., 141, 267–280.
Doyle A, Martin WJ, Funa K, Gazdar A, Carney D, Martin SE, Linnoila I, Cuttitta F, Mulshine J and Bunn P . (1985). J. Exp. Med., 161, 1135–1151.
Feldman LE, Shin KC, Natale RB and Todd RF . (1991). Cancer Res., 51, 1065–1070.
Fitter S, Tetaz TJ, Berndt MC and Ashman LK . (1995). Blood, 86, 1348–1355.
Guo X, Friess H, Graber HU, Kashiwagi M, Zimmermann A, Korc M and Buchler MW . (1996). Cancer Res., 56, 4876–4880.
Hemler ME . (1998). Curr. Opin. Cell Biol., 10, 578–585.
Hemler ME, Mannion BA and Berditchevski F . (1996). Biochim. Biophys. Acta., 1287, 67–71.
Higashiyama M, Taki T, Ieki Y, Adachi M, Huang CL, Koh T, Kodama K, Doi O and Miyake M . (1995). Cancer Res., 55, 6040–6044.
Hotta H, Ross AH, Huebner K, Isobe M, Wendeborn S, Chao MV, Ricciardi RP, Tsujimoto Y, Croce CM and Koprowski H . (1988). Cancer Res., 48, 2955–2962.
Hsu SM, Raine L and Fanger H . (1981). Am. J. Clin. Pathol., 75, 816–821.
Huang CI, Kohno N, Ogawa E, Adachi M, Taki T and Miyake M . (1998). Am. J. Pathol., 153, 973–983.
Ikeyama S, Koyama M, Yamaoko M, Sasada R and Miyake M . (1993). J. Exp. Med., 177, 1231–1237.
Inoue G, Horiike N and Onji M . (2001). Int. J. Mol. Med., 7, 67–71.
Kaprielian Z, Cho KO, Hadjiargyrou M and Patterson PH . (1995). J. Neurosci., 15, 562–573.
Kashii T, Mizushima Y, Nakagawa K, Monno S and Yano S . (1992). Anticancer Res., 12, 621–624.
Lagaudriere-Gesbert C, Lebel-Binay S, Wiertz E, Ploegh HL, Fradelizi D and Conjeaud H . (1997). J. Immunol., 158, 2790–2797.
Lantuejoul S, Moro D, Michalides RJ, Brambilla C and Brambilla E . (1998). Am. J. Surg. Pathol., 22, 1267–1276.
Le Naour F, Rubinstein E, Jasmin C, Prenant M and Boucheix C . (2000). Science, 287, 319–321.
Li J, Hu SX, Perng GS, Zhou Y, Xu K, Zhang C, Seigne J, Benedict WF and Xu HJ . (1996). Oncogene, 13, 2379–2386.
Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW and Barrett JC . (1999). Cancer Res., 59, 5724–5731.
Mabry M, Nelkin BD, Falco JP, Barr LF and Baylin SB . (1991). Cancer Cells, 3, 53–58.
Maecker HT, Todd SC and Levy S . (1997). FASEB J., 11, 428–442.
Mashimo T, Bandyopadhyay S, Goodarzi G, Watabe M, Pai SK, Gross SC and Watabe K . (2000). Biochem. Biophys. Res. Commun., 274, 370–376.
Miyado K, Yamada G, Yamada S, Hasuwa H, Nakamura Y, Ryu F, Suzuki K, Kosai K, Inoue K, Ogura A, Okabe M and Mekada E . (2000). Science, 287, 321–324.
Miyake M, Inufusa H, Adachi M, Ishida H, Hashida H, Tokuhara T and Kakehi Y . (2000). Oncogene, 19, 5221–5226.
Miyake M, Nakano K, Itoi SI, Koh T and Taki T . (1996). Cancer Res., 56, 1244–1249.
Miyake M, Nakano K, Ieki Y, Adachi M, Huang CL, Itoi S, Koh T and Taki T . (1995). Cancer Res., 55, 4127–4131.
Mountain CF . (1978). Semin. Oncol., 5, 272–279.
Nagira M, Imai T, Ishikawa I, Uwabe KI and Yoshie O . (1994). Cell Immunol., 157, 144–157.
Nakamura K, Iwamoto R and Mekada E . (1995). J. Cell Biol., 129, 1691–1705.
Oritani K, Wu X, Medina K, Hudson J, Miyake K, Gimble JM, Burstein SA and Kincade PW . (1996). Blood, 87, 2252–2261.
Rubinstein E, Le Naour F, Lagaudriere-Gesbert C, Billard M, Conjeaud H and Boucheix C . (1996). Eur. J. Immunol., 26, 2657–2665.
Saito S, Tanio Y, Tachibana I, Hayashi S, Kishimoto T and Kawase I . (1994). Lung Cancer, 10, 307–318.
Saito S, Inoue T, Kawase I, Hara H, Tanio Y, Tachibana I, Hayashi S, Watanabe M, Matsunashi M and Osaki T . (1991). Cancer Immunol. Immunother., 33, 165–170.
Salgia R and Skarin AT . (1998). J. Clin. Oncol., 16, 1207–1217.
Scheidegger EP, Lackie PM, Papay J and Roth J . (1994). Lab Invest., 70, 95–106.
Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R and Haslett C . (1999). Nat. Med., 5, 662–668.
Shaw AR, Domanska A, Mak A, Gilchrist A, Dobler K, Visser L, Poppema S, Fliegel L, Letarte M and Willett BJ . (1995). J. Biol. Chem., 270, 24092–24099.
Sho M, Adachi M, Taki T, Hashida H, Konishi T, Huang CL, Ikeda N, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H and Miyake M . (1998). Int. J. Cancer, 79, 509–516.
Shtivelman E . (1997). Oncogene, 14, 2167–2173.
Souhami RL, Beverley PC and Bobrow LG . (1987). Lancet, 2, 325–326.
Tachibana I and Hemler ME . (1999). J. Cell Biol., 146, 893–904.
Tachibana I, Bodorova J, Berditchevski F, Zutter MM and Hemler ME . (1997). J. Biol. Chem., 272, 29181–29189.
Tachibana I, Mori M, Tanio Y, Hosoe S, Sakuma T, Osaki T, Ueno, K, Kumagai T, Kijima T and Kishimoto T . (1996). Exp. Cell Res., 227, 230–239.
Tanio Y, Watanabe M, Osaki T, Tachibana I, Kawase I, Kuritani T, Saito S, Masuno T, Kodama N and Furuse K . (1992). Jpn J. Cancer Res., 83, 736–745.
Testa JE, Brooks PC, Lin JM and Quigley JP . (1999). Cancer Res., 59, 3812–3820.
Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake M and Imamura M . (1999). Br. J. Cancer, 79, 1168–1173.
White A, Lamb PW and Barrett JC . (1998). Oncogene, 16, 3143–3149.
Yang X, Wei L, Tang C, Slack R, Montgomery E and Lippman M . (2000). Clin. Cancer Res., 6, 3424–3429.
Yauch RL, Berditchevski F, Harler MB, Reichner J and Hemler ME . (1998). Mol. Biol. Cell, 9, 2751–2765.
Acknowledgements
This work was partially supported by a grant from Sankyo Foundation of Life Science, Tokyo, Japan, and by Grants-in-Aid for Cancer Research from the Ministry of Education, Science and Culture, Japan. The authors are grateful to Dr Martin E Hemler (Dana-Farber Cancer Institute, Boston) and Dr Osamu Yoshie (Kinki University School of Medicine, Osaka, Japan), for providing antibodies to tetraspanins. We also thank Yasuo Katsuki and Eiji Oiki (Osaka University Graduate School of Medicine) for technical assistance on the time-lapse videomicroscopic cell motility assay and Yoko Habe for secretarial assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Funakoshi, T., Tachibana, I., Hoshida, Y. et al. Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene 22, 674–687 (2003). https://doi.org/10.1038/sj.onc.1206106
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206106
Keywords
This article is cited by
-
Progressive slowdown/prevention of cellular senescence by CD9-targeted delivery of rapamycin using lactose-wrapped calcium carbonate nanoparticles
Scientific Reports (2017)
-
Aptamers: versatile probes for flow cytometry
Applied Microbiology and Biotechnology (2013)
-
Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer
Journal of Ovarian Research (2012)
-
CD9P-1 expression correlates with the metastatic status of lung cancer, and a truncated form of CD9P-1, GS-168AT2, inhibits in vivo tumour growth
British Journal of Cancer (2011)
-
Tetraspanins and tumor progression
Clinical & Experimental Metastasis (2011)